Aldeyra CFO Purchases $7,100 in Stock as Company Faces FDA Setback and Executive Departure
Michael Alfieri, Principal Financial Officer at Aldeyra Therapeutics, purchased 5,000 shares of common stock on March 18, 2026, paying $1.42 per share for a total of $7,100. The transaction comes after a 61% decline in the stock over the previous week, with shares trading at $1.83—about 29% above Alfieri's purchase price. The company recently recei…